Sanofi $SNY Shares Acquired by ICONIQ Capital LLC

ICONIQ Capital LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 44.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,173 shares of the company’s stock after purchasing an additional 5,298 shares during the period. ICONIQ Capital LLC’s holdings in Sanofi were worth $952,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SNY. Accent Capital Management LLC acquired a new stake in Sanofi during the first quarter valued at approximately $29,000. Eastern Bank lifted its stake in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares during the last quarter. Brentview Investment Management LLC acquired a new stake in Sanofi during the first quarter valued at approximately $42,000. Finally, UMB Bank n.a. lifted its stake in Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock valued at $62,000 after purchasing an additional 264 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNY has been the subject of several research analyst reports. Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Sanofi in a research report on Tuesday, August 5th. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Finally, Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $62.00.

Sanofi Stock Up 1.5%

SNY stock opened at $51.35 on Friday. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company has a market cap of $126.09 billion, a price-to-earnings ratio of 12.34, a PEG ratio of 1.22 and a beta of 0.48. The company has a 50 day moving average of $48.62 and a two-hundred day moving average of $51.71.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same quarter in the previous year, the company earned $1.73 EPS. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.